Dr Reddy's reaping benefits of domestic market focus, outperforms peers

Firm has outperformed domestic pharma market in 7 of last 8 quarters

The focus of Dr Reddy’s Laboratories (DRL) on the domestic market seems to be paying off. This has helped the company outperform the domestic pharma market in seven of the last eight quarters. 

In November, DRL registered growth of 28 per cent year-on-year (YoY), which was the highest among peers and double that of the industry growth (14.5 per cent). The trailing twelve-month average, at 15.4 per cent, was also higher than the pharma growth of 9.8 per cent. 

Even as the domestic performance remains strong, the firm has improved its performance in emerging markets, including China.
 

In the US, it has